Financial and organizational information - With PKD Connect, no one will ever face polycystic kidney disease alone ... Industry relations policy · Whistleblower ...
Since the Foundation's establishment in 1982, it has invested nearly $60 million in dedicated PKD research, clinical and scientific grant awards, ...
Nick Henley, Director, Investor Relations. (281) 406-2082. nick.henley@parkerdrilling.com · View all news. Investor Alerts. To opt-in for investor email alerts ...
INVESTORS. ; $2.34. NASDAQ: RGLS ; -$0.22 (-8.59%). Change ; 295.3K · Volume ; $153.2M · Market Cap.
People also ask
What is the prognosis for PKD?
What is the difference between PKD1 and 2?
Is PKD dominant or recessive?
What is the new medication for PKD?
The Polycystic Kidney Disease Research Resource Consortium (PKD RRC) develops and shares investigative resources, reagents and expertise with the broader ...
... Polycystic Kidney Disease (ADPKD), XRx-101 for ... Investor Relations. Investors. Investors. Overview ... Investor Relations. Allen Davidoff CEO T: 403-455-7727
The PKD Foundation of Canada is committed to raising funds towards finding a treatment and cure for polycystic kidney disease (PKD). Please find our most recent ...
We are a global alliance of patient organizations dedicated to a cure for Polycystic Kidney Disease (PKD) ...
Polycystic Kidney Disease Charity supports everyone in the UK affected by polycystic kidney disease (PKD), raises awareness and funds research.
The PKD Foundation is a not-for-profit organization dedicated to finding treatments and a cure for polycystic kidney disease (PKD).